Show simple item record

dc.contributor.authorAragon-Ching, J
dc.contributor.authorChoudhury, Ananya
dc.contributor.authorMargulis, V
dc.contributor.authorYu, E
dc.date.accessioned2019-06-25T09:32:55Z
dc.date.available2019-06-25T09:32:55Z
dc.date.issued2019en
dc.identifier.citationAragon-Ching JB, Choudhury A, Margulis V, Yu EY. Formidable scenarios in urothelial and variant cancers of the urinary tract. Am Soc Clin Oncol Educ Book. 2019;39:262-75.en
dc.identifier.pmid31099661en
dc.identifier.doi10.1200/EDBK_237451en
dc.identifier.urihttp://hdl.handle.net/10541/621897
dc.description.abstractDiagnostic and therapeutic challenges in the field of bladder and upper tract cancers provide opportunities for multidisciplinary care. Urothelial cancers make up the majority of the histologic subtype of bladder and upper tract cancers. Although the existence of variant histology, nonurothelial cancers, and urethral cancers is rare, these cancers pose a challenging clinical dilemma given the lack of well-defined consensus treatment guidelines. This review focuses on key issues of treatment: cisplatin ineligibility with emphasis on the definition, nuances of chemotherapy and frontline immune checkpoint inhibitor therapy, use of radiation in bladder-preservation strategies, upper tract urothelial cancer management, and highlights of urothelial variants and nonurothelial tumors and management.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/EDBK_237451en
dc.titleFormidable scenarios in urothelial and variant cancers of the urinary tracten
dc.typeArticleen
dc.contributor.departmentInova Schar Cancer Institute, Fairfax, VA2 The Christie National Health Service Foundation Trust, Manchester, United Kingdomen
dc.identifier.journalAmerican Society of Clinical Oncology Educational Booken
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record